Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
valsartan + hydrochlorothiazide (Changzhou Siyao Pharmaceuticals)
- Development stage
- Unknown
- Lead developer
- Changzhou Siyao Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Jin Xieke is a fixed-dose combination pharmaceutical product containing valsartan and hydrochlorothiazide. Valsartan is an angiotensin II receptor blocker (ARB) that works by selectively antagonizing the AT1 receptor, leading to vasodilation and decreased aldosterone production. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubules of the kidneys, promoting the excretion of sodium and water. Developed by Changzhou Siyao Pharmaceutical, Jin Xieke is used for the management of primary hypertension, particularly in patients who require combination therapy to achieve blood pressure targets. It is a generic version of the reference drug Co-Diovan.
- Brand names
- Jin Xieke
- Other names
- valsartan and hydrochlorothiazide tablets
02
Targets
AGTR2 (AT2)AGTR1 (Angiotensin II Type-1 receptor)CA (Carbonic anhydrase)
Beyond the preview
Go deeper on valsartan + hydrochlorothiazide (Changzhou Siyao Pharmaceuticals).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on valsartan + hydrochlorothiazide (Changzhou Siyao Pharmaceuticals).